

Our ref: IG/FOI/FOI.181.25

29 January 2025

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 23 January 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does hold the information that you require.

For ease of reference your request is set out below and my response follows.

Your Freedom of Information (FOI) Request:

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone).
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone).
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine).
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone).
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate).
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine).
- R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone).
- (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab).

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

- R-GemOX (rituximab, gemcitabine and oxaliplatin).
- Axicabtagene ciloleucel.
- Tisagenlecleucel.
- Epcoritamab.
- Loncastuximab tesirine.
- Glofitamab.
- Any other SACT.
- Stem cell transplant or bone marrow transplant (autologous or allogeneic).

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta).
- Tisagenlecleucel.
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine).
- R-GemOX (rituximab, gemcitabine and oxaliplatin).
- Stem cell transplant or bone marrow transplant (autologous or allogeneic).
- Any other treatments.

Q4. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel).
- Stem cell transplant or bone marrow transplant (autologous or allogeneic).
- Any other treatment.

Powys Response:

S21 - Under Section 21 of the Freedom of Information Act, an organisation does not have to respond to a request if the information being sought is reasonably accessible to the applicant by another means. Section 21 is absolute and therefore does not require a public interest test. Powys Teaching Health Board (PTHB) has applied this exemption to your request as the information you are seeking is available in the public domain.

To comply with our obligation under Section 16 of the Act, the duty to provide help and assistance. I can confirm the Powys Teaching Health Board (PTHB) has responded to a request recently of a similar nature which we feel answers the questions you raised. Please visit the following link to access the health board's disclosure log and the previous response you need to review is FOI.24.R.267 (July): [Disclosure Log - Powys Teaching Health Board](#)

If any part of your request has not been answered by this response, please submit a new request addressing the missing information only

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please

contact us directly at the address below or register your complaint via Powys.FOI@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



Richard Stratton
Assistant Medical Director: Primary Care and Community; Service Development

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.